. SARC028 samples reveal an interplay between TGFβ, interferon signaling and low HLA class I expression as contributors to Ewing sarcoma checkpoint blockade resistance. Clin Cancer Res. 2025-07-08; doi: 10.1158/1078-0432.CCR-24-3882. nihFormattedCitation: Daley JD, Mukherjee E, Ferraro D, Bhaskar S, Green A, Meyer EM, Tawbi H, Burgess M, Bruno TC, Cillo AR, Bailey KM. SARC028 samples reveal an interplay between TGFβ, interferon signaling and low HLA class I expression as contributors to Ewing sarcoma checkpoint blockade resistance. Clin Cancer Res. 2025;.. PubMed PMID: 40627445.
. Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma. J Immunother Cancer. 2025-06-15;13(6): doi: 10.1136/jitc-2025-011537. nihFormattedCitation: Dadey RE, Li R, Griner J, Chen J, Singh A, Isett B, Newman S, Augustin R, Li A, Manning JA, Monga SP, Singhi A, Geller DAA, Krieg C, Zervantonakis IK, Luke JJ, Bao R. Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma. J Immunother Cancer. 2025;13(6).. PubMed PMID: 40518290.
. Aged and BRCA mutated stromal cells drive epithelial cell transformation. Cancer Discov. 2025-06-03; doi: 10.1158/2159-8290.CD-24-0805. nihFormattedCitation: Garcia GL, Orellana T, Gorecki G, Frisbie L, Baruwal R, Suresh S, Goldfeld E, Beddows I, MacFawn IP, Britt AK, Hale MM, Elhaw AT, Isett BR, Hempel N, Bao R, Shen H, Buckanovich RJ, Finkel T, Drapkin R, Soong TR, Bruno TC, Atiya HI, Coffman LG. Aged and BRCA mutated stromal cells drive epithelial cell transformation. Cancer Discov. 2025;. PMCID: PMC12130807.. PubMed PMID: 40084985; PMCID: PMC12130807.
. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers. Nat Commun. 2025-05-30;16(1):5009. doi: 10.1038/s41467-025-60457-2. nihFormattedCitation: Lehrich BM, Delgado ER, Yasaka TM, Liu S, Cao C, Liu Y, Taheri MN, Guan X, Koeppen H, Singh S, Meadows V, Liu JJ, Singh-Varma A, Krutsenko Y, Poddar M, Hitchens TK, Foley LM, Liang B, Rialdi A, Rai RP, Patel P, Riley M, Bell A, Raeman R, Dadali T, Luke JJ, Guccione E, Ebrahimkhani MR, Lujambio A, Chen X, Maier M, Wang Y, Broom W, Tao J, Monga SP. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers. Nat Commun. 2025;16(1):5009. PMCID: PMC12122713.. PubMed PMID: 40442146; PMCID: PMC12122713.
. Integrative characterization of MYC RNA-binding function. Cell Genom. 2025-05-13;100878. doi: 10.1016/j.xgen.2025.100878. nihFormattedCitation: Li S, Wang Z, Wang X, Wang Y, Pattarayan D, Zhang Y, Nguyen P, Bhuniya A, Chen Y, Huang H, Huang Y, Wang L, Wang J, Li S, Zhang M, Liu Y, Lee N, Yang D. Integrative characterization of MYC RNA-binding function. Cell Genom. 2025;:100878.. PubMed PMID: 40378850.
. Reply to: "Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits" and "Annual Versus Biennial Mammographic Screening". J Clin Oncol. 2025-03-01;JCO2402373. doi: 10.1200/JCO-24-02373. nihFormattedCitation: Zuley ML, Bandos AI, Duffy SW, Logue D, Bhargava R, McAuliffe PF, Brufsky AM, Nishikawa RM. Reply to: "Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits" and "Annual Versus Biennial Mammographic Screening". J Clin Oncol. 2025;:JCO2402373. PMCID: PMC11867873.. PubMed PMID: 39689268; PMCID: PMC11867873.
. Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025-02-12;13(2): doi: 10.1136/jitc-2024-009568. nihFormattedCitation: Tompkins AG, Gray ZN, Dadey RE, Zenkin S, Batavani N, Newman S, Amouzegar A, Ak M, Ak N, Pak TY, Peddagangireddy V, Mamindla P, Amjadzadeh M, Behr S, Goodman A, Ploucha DL, Kirkwood JM, Zarour HM, Najjar YG, Davar D, Tatsuoka C, Colen RR, Luke JJ, Bao R. Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025;13(2). PMCID: PMC11822426.. PubMed PMID: 39939139; PMCID: PMC11822426.
. Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. J Natl Compr Canc Netw. 2024-12-27;1-7. doi: 10.6004/jnccn.2024.7063. nihFormattedCitation: Dietz MS, Al-Ibraheemi A, Davis JL, Hawkins CM, Craig BT, Dasgupta R, Geller DS, Shulman DS, Cohen-Gogo S, Gupta A, Whiteway SL, Slotkin EK, Heske CM, Ahmed SK, Indelicato DJ, Albert CM, Montgomery N, Sandberg JK, Grier HE, Krailo M, Isakoff MS, Rubin E, Lawlor ER, DuBois SG, Mascarenhas L, Grohar PJ, Binitie O, Reed D, Janeway K, Roberts RD, Bailey KM. Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. J Natl Compr Canc Netw. 2024;:1-7. PMCID: PMC11881167.. PubMed PMID: 39729709; PMCID: PMC11881167.
. Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest. 2024-11-15;134(22): doi: 10.1172/JCI176851. nihFormattedCitation: Wang S, Huang T, Wu Q, Yuan H, Wu X, Yuan F, Duan T, Taori S, Zhao Y, Snyder NW, Placantonakis DG, Rich JN. Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest. 2024;134(22). PMCID: PMC11563687.. PubMed PMID: 39545414; PMCID: PMC11563687.
. Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival. J Clin Oncol. 2024-11-10;JCO2400285. doi: 10.1200/JCO.24.00285. nihFormattedCitation: Zuley ML, Bandos AI, Duffy SW, Logue D, Bhargava R, McAuliffe PF, Brufsky AM, Nishikawa RM. Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival. J Clin Oncol. 2024;:JCO2400285. PMCID: PMC11540751.. PubMed PMID: 39167740; PMCID: PMC11540751.
. Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2. Cell Metab. 2024-11-05; doi: 10.1016/j.cmet.2024.09.014. nihFormattedCitation: Lv D, Dixit D, Cruz AF, Kim LJY, Duan L, Xu X, Wu Q, Zhong C, Lu C, Gersey ZC, Gimple RC, Xie Q, Yang K, Liu X, Fang X, Wu X, Kidwell RL, Wang X, Bao S, He HH, Locasale JW, Agnihotri S, Rich JN. Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2. Cell Metab. 2024;. PMCID: PMC11726586.. PubMed PMID: 39454581; PMCID: PMC11726586.
. Changes in Reader Performance During Sequential Reading of Breast Cancer Screening Digital Breast Tomosynthesis Examinations. Radiology. 2024-11-01;313(2):e232885. doi: 10.1148/radiol.232885. nihFormattedCitation: Abbey CK, Bandos AI, Parthasarathy MK, Webster MA, Zuley ML. Changes in Reader Performance During Sequential Reading of Breast Cancer Screening Digital Breast Tomosynthesis Examinations. Radiology. 2024;313(2):e232885. PMCID: PMC11605108.. PubMed PMID: 39530892; PMCID: PMC11605108.
. Paracrine Ovarian Cancer Cell-Derived CSF1 Signaling Regulates Macrophage Migration Dynamics in a 3D Microfluidic Model that Recapitulates in vivo Infiltration Patterns in Patient-Derived Xenografts. Adv Healthc Mater. 2024-11-01;e2401719. doi: 10.1002/adhm.202401719. nihFormattedCitation: Scott AL, Jazwinska DE, Kulawiec DG, Zervantonakis IK. Paracrine Ovarian Cancer Cell-Derived CSF1 Signaling Regulates Macrophage Migration Dynamics in a 3D Microfluidic Model that Recapitulates in vivo Infiltration Patterns in Patient-Derived Xenografts. Adv Healthc Mater. 2024;:e2401719. PMCID: PMC11560735.. PubMed PMID: 38807270; PMCID: PMC11560735.
. Ten challenges and opportunities in computational immuno-oncology. J Immunother Cancer. 2024-10-26;12(10): doi: 10.1136/jitc-2024-009721. nihFormattedCitation: Bao R, Hutson A, Madabhushi A, Jonsson VD, Rosario SR, Barnholtz-Sloan JS, Fertig EJ, Marathe H, Harris L, Altreuter J, Chen Q, Dignam J, Gentles AJ, Gonzalez-Kozlova E, Gnjatic S, Kim E, Long M, Morgan M, Ruppin E, Valen DV, Zhang H, Vokes N, Meerzaman D, Liu S, Van Allen EM, Xing Y. Ten challenges and opportunities in computational immuno-oncology. J Immunother Cancer. 2024;12(10). PMCID: PMC11529678.. PubMed PMID: 39461879; PMCID: PMC11529678.
. The dark side of human hepatocyte plasticity. Gastroenterology. 2024-10-01; doi: 10.1053/j.gastro.2024.06.011. nihFormattedCitation: Ko S, Monga SP. The dark side of human hepatocyte plasticity. Gastroenterology. 2024;. PMCID: PMC11980431.. PubMed PMID: 38936779; PMCID: PMC11980431.
. Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming. Nat Cancer. 2024-07-01; doi: 10.1038/s43018-024-00748-7. nihFormattedCitation: Wu X, Yuan H, Wu Q, Gao Y, Duan T, Yang K, Huang T, Wang S, Yuan F, Lee D, Taori S, Plute T, Heissel S, Alwaseem H, Isay-Del Viscio M, Molina H, Agnihotri S, Hsu DJ, Zhang N, Rich JN. Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming. Nat Cancer. 2024;. PMCID: PMC11552442.. PubMed PMID: 38519786; PMCID: PMC11552442.
. Career trajectories of MD-PhD physician scientists: The loss of women investigators. Cancer Cell. 2024-05-13; doi: 10.1016/j.ccell.2024.04.006. nihFormattedCitation: Steinman RA, Gandy LM, Qi H, Fertig EJ, Blackford AL, Grandis JR. Career trajectories of MD-PhD physician scientists: The loss of women investigators. Cancer Cell. 2024;.. PubMed PMID: 38701793.
. Facts and hopes in using omics to advance combined immunotherapy strategies. Clin Cancer Res. 2024-05-01; doi: 10.1158/1078-0432.CCR-22-2241. nihFormattedCitation: Augustin RC, Cai WL, Luke JJ, Bao R. Facts and hopes in using omics to advance combined immunotherapy strategies. Clin Cancer Res. 2024;. PMCID: PMC11062841.. PubMed PMID: 38236069; PMCID: PMC11062841.
. Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer. J Clin Oncol. 2024-05-01;JCO2301080. doi: 10.1200/JCO.23.01080. nihFormattedCitation: Chen L, Wang Y, Cai C, Ding Y, Kim RS, Lipchik C, Gavin PG, Yothers G, Allegra CJ, Petrelli NJ, Suga JM, Hopkins JO, Saito NG, Evans T, Jujjavarapu S, Wolmark N, Lucas PC, Paik S, Sun M, Pogue-Geile KL, Lu X. Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer. J Clin Oncol. 2024;:JCO2301080. PMCID: PMC11095904.. PubMed PMID: 38315963; PMCID: PMC11095904.
. A Path to Persistence after EGFR Inhibition. Cancer Res. 2024-04-15;84(8):1188-1190. doi: 10.1158/0008-5472.CAN-24-0274. nihFormattedCitation: Rumde PH, Burns TF. A Path to Persistence after EGFR Inhibition. Cancer Res. 2024;84(8):1188-1190. PMCID: PMC11090642.. PubMed PMID: 38616658; PMCID: PMC11090642.
. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer. Nat Commun. 2024-04-12;15(1):3178. doi: 10.1038/s41467-024-47433-y. nihFormattedCitation: Wang Y, Pattarayan D, Huang H, Zhao Y, Li S, Wang Y, Zhang M, Li S, Yang D. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer. Nat Commun. 2024;15(1):3178. PMCID: PMC11015024.. PubMed PMID: 38609378; PMCID: PMC11015024.
. Addition of Contrast-enhanced Mammography to Tomosynthesis for Breast Cancer Detection in Women with a Personal History of Breast Cancer: Prospective TOCEM Trial Interim Analysis. Radiology. 2024-04-01;311(1):e231991. doi: 10.1148/radiol.231991. nihFormattedCitation: Berg WA, Berg JM, Bandos AI, Vargo A, Chough DM, Lu AH, Ganott MA, Kelly AE, Nair BE, Hartman JY, Waheed U, Hakim CM, Harnist KS, Reginella RF, Shinde DD, Carlin BA, Cohen CS, Wallace LP, Sumkin JH, Zuley ML. Addition of Contrast-enhanced Mammography to Tomosynthesis for Breast Cancer Detection in Women with a Personal History of Breast Cancer: Prospective TOCEM Trial Interim Analysis. Radiology. 2024;311(1):e231991. PMCID: PMC11070607.. PubMed PMID: 38687218; PMCID: PMC11070607.
. Therapeutic Hope on the Surface of Ewing Sarcoma. Clin Cancer Res. 2024-03-01; doi: 10.1158/1078-0432.CCR-23-3138. nihFormattedCitation: Bailey KM. Therapeutic Hope on the Surface of Ewing Sarcoma. Clin Cancer Res. 2024;. PMCID: PMC10922950.. PubMed PMID: 38113033; PMCID: PMC10922950.
. Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism. Nat Cancer. 2024-01-01; doi: 10.1038/s43018-023-00658-0. nihFormattedCitation: Zhao L, Qiu Z, Yang Z, Xu L, Pearce TM, Wu Q, Yang K, Li F, Saulnier O, Fei F, Yu H, Gimple RC, Varadharajan V, Liu J, Hendrikse LD, Fong V, Wang W, Zhang J, Lv D, Lee D, Lehrich BM, Jin C, Ouyang L, Dixit D, Wu H, Wang X, Sloan AE, Wang X, Huan T, Mark Brown J, Goldman SA, Taylor MD, Zhou S, Rich JN. Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism. Nat Cancer. 2024;.. PubMed PMID: 38172338.
. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. Mol Cell. 2023-12-07; doi: 10.1016/j.molcel.2023.10.025. nihFormattedCitation: Lv D, Zhong C, Dixit D, Yang K, Wu Q, Godugu B, Prager BC, Zhao G, Wang X, Xie Q, Bao S, He C, Heiland DH, Rosenfeld MG, Rich JN. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. Mol Cell. 2023;. PMCID: PMC10842222.. PubMed PMID: 37979586; PMCID: PMC10842222.
. Beyond matrix stiffness: targeting force-induced cancer drug resistance. Trends Cancer. 2023-11-01; doi: 10.1016/j.trecan.2023.07.006. nihFormattedCitation: Kalli M, Poskus MD, Stylianopoulos T, Zervantonakis IK. Beyond matrix stiffness: targeting force-induced cancer drug resistance. Trends Cancer. 2023;. PMCID: PMC10592424.. PubMed PMID: 37558577; PMCID: PMC10592424.
. Statins as a Secondary Preventive Agent for Metastatic Cancer. J Thorac Oncol. 2023-11-01;18(11):e125-e126. doi: 10.1016/j.jtho.2023.07.027. nihFormattedCitation: Marti JLG, Wells JZ, Wells A. Statins as a Secondary Preventive Agent for Metastatic Cancer. J Thorac Oncol. 2023;18(11):e125-e126.. PubMed PMID: 37879767.
. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. J Immunother Cancer. 2023-10-01;11(10): doi: 10.1136/jitc-2023-007567. nihFormattedCitation: Augustin RC, Newman S, Li A, Joy M, Lyons M, Pham MP, Lucas P, Smith K, Sander C, Isett B, Davar D, Najjar YG, Zarour HM, Kirkwood JM, Luke JJ, Bao R. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. J Immunother Cancer. 2023;11(10). PMCID: PMC10603348.. PubMed PMID: 37857525; PMCID: PMC10603348.
. The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer. Cancer Res. 2023-08-15;83(16):2656-2674. doi: 10.1158/0008-5472.CAN-23-0539. nihFormattedCitation: Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC, Oesterreich S, Lee AV. The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer. Cancer Res. 2023;83(16):2656-2674. PMCID: PMC10527051.. PubMed PMID: 37272757; PMCID: PMC10527051.
. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy. Clin Cancer Res. 2023-05-15;29(10):1969-1983. doi: 10.1158/1078-0432.CCR-22-2254. nihFormattedCitation: Cole AJ, Panesso-Gómez S, Shah JS, Ebai T, Jiang Q, Gumusoglu-Acar E, Bello MG, Vlad A, Modugno F, Edwards RP, Buckanovich RJ. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy. Clin Cancer Res. 2023;29(10):1969-1983. PMCID: PMC10192102.. PubMed PMID: 36795892; PMCID: PMC10192102.
. Lysine catabolism reprograms tumour immunity through histone crotonylation. Nature. 2023-05-01;617(7962):818-826. doi: 10.1038/s41586-023-06061-0. nihFormattedCitation: Yuan H, Wu X, Wu Q, Chatoff A, Megill E, Gao J, Huang T, Duan T, Yang K, Jin C, Yuan F, Wang S, Zhao L, Zinn PO, Abdullah KG, Zhao Y, Snyder NW, Rich JN. Lysine catabolism reprograms tumour immunity through histone crotonylation. Nature. 2023;617(7962):818-826. PMCID: PMC11089809.. PubMed PMID: 37198486; PMCID: PMC11089809.
. Growth factor receptor signaling induces mitophagy through epitranscriptomic regulation. Autophagy. 2023-03-01;19(3):1034-1035. doi: 10.1080/15548627.2022.2114765. nihFormattedCitation: Lv D, Yang K, Rich JN. Growth factor receptor signaling induces mitophagy through epitranscriptomic regulation. Autophagy. 2023;19(3):1034-1035. PMCID: PMC9980508.. PubMed PMID: 35980802; PMCID: PMC9980508.
. High-Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single-Cell Level. Small. 2023-02-01;19(6):e2206754. doi: 10.1002/smll.202206754. nihFormattedCitation: Zhou M, Ma Y, Chiang CC, Rock EC, Luker KE, Luker GD, Chen YC. High-Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single-Cell Level. Small. 2023;19(6):e2206754. PMCID: PMC9908848.. PubMed PMID: 36449634; PMCID: PMC9908848.
. Superenhancer activation of KLHDC8A drives glioma ciliation and hedgehog signaling. J Clin Invest. 2023-01-17;133(2): doi: 10.1172/JCI163592. nihFormattedCitation: Lee D, Gimple RC, Wu X, Prager BC, Qiu Z, Wu Q, Daggubati V, Mariappan A, Gopalakrishnan J, Sarkisian MR, Raleigh DR, Rich JN. Superenhancer activation of KLHDC8A drives glioma ciliation and hedgehog signaling. J Clin Invest. 2023;133(2). PMCID: PMC9843063.. PubMed PMID: 36394953; PMCID: PMC9843063.
. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov. 2023-01-09;13(1):23-40. doi: 10.1158/2159-8290.CD-22-0475. nihFormattedCitation: Onkar SS, Carleton NM, Lucas PC, Bruno TC, Lee AV, Vignali DAA, Oesterreich S. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov. 2023;13(1):23-40. PMCID: PMC9833841.. PubMed PMID: 36620880; PMCID: PMC9833841.
. Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts. Gastroenterology. 2023-01-01;164(1):117-133.e7. doi: 10.1053/j.gastro.2022.09.028. nihFormattedCitation: Paniccia A, Polanco PM, Boone BA, Wald AI, McGrath K, Brand RE, Khalid A, Kubiliun N, O'Broin-Lennon AM, Park WG, Klapman J, Tharian B, Inamdar S, Fasanella K, Nasr J, Chennat J, Das R, DeWitt J, Easler JJ, Bick B, Singh H, Fairley KJ, Sarkaria S, Sawas T, Skef W, Slivka A, Tavakkoli A, Thakkar S, Kim V, Vanderveldt HD, Richardson A, Wallace MB, Brahmbhatt B, Engels M, Gabbert C, Dugum M, El-Dika S, Bhat Y, Ramrakhiani S, Bakis G, Rolshud D, Millspaugh G, Tielleman T, Schmidt C, Mansour J, Marsh W, Ongchin M, Centeno B, Monaco SE, Ohori NP, Lajara S, Thompson ED, Hruban RH, Bell PD, Smith K, Permuth JB, Vandenbussche C, Ernst W, Grupillo M, Kaya C, Hogg M, He J, Wolfgang CL, Lee KK, Zeh H, Zureikat A, Nikiforova MN, Singhi AD. Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts. Gastroenterology. 2023;164(1):117-133.e7. PMCID: PMC9844531.. PubMed PMID: 36209796; PMCID: PMC9844531.
. Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation. Cancer Res. 2022-12-16;82(24):4680-4693. doi: 10.1158/0008-5472.CAN-22-1294. nihFormattedCitation: Atiya HI, Frisbie L, Goldfeld E, Orellana T, Donnellan N, Modugno F, Calderon M, Watkins S, Zhang R, Elishaev E, Soong TR, Vlad A, Coffman L. Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation. Cancer Res. 2022;82(24):4680-4693. PMCID: PMC9755968.. PubMed PMID: 36219681; PMCID: PMC9755968.
. Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response. Sci Adv. 2022-12-09;8(49):eadd0005. doi: 10.1126/sciadv.add0005. nihFormattedCitation: Wang Y, Zhao Y, Guo W, Yadav GS, Bhaskarla C, Wang Z, Wang X, Li S, Wang Y, Chen Y, Pattarayan D, Xie W, Li S, Lu B, Kammula US, Zhang M, Yang D. Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response. Sci Adv. 2022;8(49):eadd0005. PMCID: PMC9728976.. PubMed PMID: 36475797; PMCID: PMC9728976.
. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov. 2022-12-06;OF1-OF18. doi: 10.1158/2159-8290.CD-22-0475. nihFormattedCitation: Onkar SS, Carleton NM, Lucas PC, Bruno TC, Lee AV, Vignali DAA, Oesterreich S. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov. 2022;:OF1-OF18.. PubMed PMID: 36473061.
. Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. Clin Cancer Res. 2022-11-14;28(22):4968-4982. doi: 10.1158/1078-0432.CCR-22-1471. nihFormattedCitation: Cillo AR, Mukherjee E, Bailey NG, Onkar S, Daley J, Salgado C, Li X, Liu D, Ranganathan S, Burgess M, Sembrat J, Weiss K, Watters R, Bruno TC, Vignali DAA, Bailey KM. Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks. Clin Cancer Res. 2022;28(22):4968-4982. PMCID: PMC9669190.. PubMed PMID: 36074145; PMCID: PMC9669190.
. Interpretable deep learning for chromatin-informed inference of transcriptional programs driven by somatic alterations across cancers. Nucleic Acids Res. 2022-10-28;50(19):10869-10881. doi: 10.1093/nar/gkac881. nihFormattedCitation: Tao Y, Ma X, Palmer D, Schwartz R, Lu X, Osmanbeyoglu HU. Interpretable deep learning for chromatin-informed inference of transcriptional programs driven by somatic alterations across cancers. Nucleic Acids Res. 2022;50(19):10869-10881. PMCID: PMC9638905.. PubMed PMID: 36243974; PMCID: PMC9638905.
. Single-cell spatial transcriptomics reveals a dynamic control of metabolic zonation and liver regeneration by endothelial cell Wnt2 and Wnt9b. Cell Rep Med. 2022-10-18;3(10):100754. doi: 10.1016/j.xcrm.2022.100754. nihFormattedCitation: Hu S, Liu S, Bian Y, Poddar M, Singh S, Cao C, McGaughey J, Bell A, Blazer LL, Adams JJ, Sidhu SS, Angers S, Monga SP. Single-cell spatial transcriptomics reveals a dynamic control of metabolic zonation and liver regeneration by endothelial cell Wnt2 and Wnt9b. Cell Rep Med. 2022;3(10):100754. PMCID: PMC9588996.. PubMed PMID: 36220068; PMCID: PMC9588996.
. A Druggable Rheostat for Ewing Sarcoma? Clin Cancer Res. 2022-10-14;28(20):4360-4362. doi: 10.1158/1078-0432.CCR-22-1794. nihFormattedCitation: Weiss KR, Bailey KM. A Druggable Rheostat for Ewing Sarcoma? Clin Cancer Res. 2022;28(20):4360-4362. PMCID: PMC9588653.. PubMed PMID: 35921177; PMCID: PMC9588653.
. Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer. 2022-09-01;22(9):497-514. doi: 10.1038/s41568-022-00486-x. nihFormattedCitation: Gimple RC, Yang K, Halbert ME, Agnihotri S, Rich JN. Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer. 2022;22(9):497-514.. PubMed PMID: 35710946.
. HuR-dependent SOD2 protein synthesis is an early adaptation to anchorage-independence. Redox Biol. 2022-07-01;53102329. doi: 10.1016/j.redox.2022.102329. nihFormattedCitation: Kim YS, Tang PW, Welles JE, Pan W, Javed Z, Elhaw AT, Mythreye K, Kimball SR, Hempel N. HuR-dependent SOD2 protein synthesis is an early adaptation to anchorage-independence. Redox Biol. 2022;53:102329. PMCID: PMC9121325.. PubMed PMID: 35594792; PMCID: PMC9121325.
. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022-06-01;22(6):323-339. doi: 10.1038/s41568-022-00454-5. nihFormattedCitation: Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022;22(6):323-339. PMCID: PMC9149051.. PubMed PMID: 35264777; PMCID: PMC9149051.
. An integral genomic signature approach for tailored cancer therapy using genome-wide sequencing data. Nat Commun. 2022-05-26;13(1):2936. doi: 10.1038/s41467-022-30449-7. nihFormattedCitation: Wang XS, Lee S, Zhang H, Tang G, Wang Y. An integral genomic signature approach for tailored cancer therapy using genome-wide sequencing data. Nat Commun. 2022;13(1):2936. PMCID: PMC9135729.. PubMed PMID: 35618721; PMCID: PMC9135729.
. Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. Nat Cancer. 2022-05-01;3(5):629-648. doi: 10.1038/s43018-022-00348-3. nihFormattedCitation: Golbourn BJ, Halbert ME, Halligan K, Varadharajan S, Krug B, Mbah NE, Kabir N, Stanton AJ, Locke AL, Casillo SM, Zhao Y, Sanders LM, Cheney A, Mullett SJ, Chen A, Wassell M, Andren A, Perez J, Jane EP, Premkumar DRD, Koncar RF, Mirhadi S, McCarl LH, Chang YF, Wu YL, Gatesman TA, Cruz AF, Zapotocky M, Hu B, Kohanbash G, Wang X, Vartanian A, Moran MF, Lieberman F, Amankulor NM, Wendell SG, Vaske OM, Panigrahy A, Felker J, Bertrand KC, Kleinman CL, Rich JN, Friedlander RM, Broniscer A, Lyssiotis C, Jabado N, Pollack IF, Mack SC, Agnihotri S. Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. Nat Cancer. 2022;3(5):629-648. PMCID: PMC9551679.. PubMed PMID: 35422502; PMCID: PMC9551679.
. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022-05-01;71(5):961-973. doi: 10.1136/gutjnl-2020-322595. nihFormattedCitation: Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022;71(5):961-973. PMCID: PMC8511349.. PubMed PMID: 33849943; PMCID: PMC8511349.
. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun. 2022-04-19;13(1):2011. doi: 10.1038/s41467-022-29498-9. nihFormattedCitation: Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun. 2022;13(1):2011. PMCID: PMC9019037.. PubMed PMID: 35440136; PMCID: PMC9019037.
. Patient-derived explants as tumor models. Cancer Cell. 2022-04-11;40(4):348-350. doi: 10.1016/j.ccell.2022.03.004. nihFormattedCitation: Hubert CG, Rich JN. Patient-derived explants as tumor models. Cancer Cell. 2022;40(4):348-350.. PubMed PMID: 35364017.
. Fatty acid nitroalkene reversal of established lung fibrosis. Redox Biol. 2022-04-01;50102226. doi: 10.1016/j.redox.2021.102226. nihFormattedCitation: Koudelka A, Cechova V, Rojas M, Mitash N, Bondonese A, St Croix C, Ross MA, Freeman BA. Fatty acid nitroalkene reversal of established lung fibrosis. Redox Biol. 2022;50:102226. PMCID: PMC8844680.. PubMed PMID: 35150970; PMCID: PMC8844680.
. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res. 2022-04-01;82(7):1321-1339. doi: 10.1158/0008-5472.CAN-21-2576. nihFormattedCitation: Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res. 2022;82(7):1321-1339. PMCID: PMC8983597.. PubMed PMID: 35078818; PMCID: PMC8983597.
. ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance. J Clin Invest. 2022-03-15;132(6): doi: 10.1172/JCI143397. nihFormattedCitation: Jiang L, Hao Y, Shao C, Wu Q, Prager BC, Gimple RC, Sulli G, Kim LJ, Zhang G, Qiu Z, Zhu Z, Fu XD, Rich JN. ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance. J Clin Invest. 2022;132(6). PMCID: PMC8920333.. PubMed PMID: 35133980; PMCID: PMC8920333.
. Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. Cancer Discov. 2022-02-01;12(2):502-521. doi: 10.1158/2159-8290.CD-20-1848. nihFormattedCitation: Qiu Z, Zhao L, Shen JZ, Liang Z, Wu Q, Yang K, Min L, Gimple RC, Yang Q, Bhargava S, Jin C, Kim C, Hinz D, Dixit D, Bernatchez JA, Prager BC, Zhang G, Dong Z, Lv D, Wang X, Kim LJY, Zhu Z, Jones KA, Zheng Y, Wang X, Siqueira-Neto JL, Chavez L, Fu XD, Spruck C, Rich JN. Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. Cancer Discov. 2022;12(2):502-521. PMCID: PMC8831451.. PubMed PMID: 34615656; PMCID: PMC8831451.
. Coupling high-throughput mapping with proteomics analysis delineates cis-regulatory elements at high resolution. Nucleic Acids Res. 2022-01-11;50(1):e5. doi: 10.1093/nar/gkab890. nihFormattedCitation: Wu T, Jiang D, Zou M, Sun W, Wu D, Cui J, Huntress I, Peng X, Li G. Coupling high-throughput mapping with proteomics analysis delineates cis-regulatory elements at high resolution. Nucleic Acids Res. 2022;50(1):e5. PMCID: PMC8754656.. PubMed PMID: 34634809; PMCID: PMC8754656.
. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. Sci Transl Med. 2022-01-05;14(626):eabf3917. doi: 10.1126/scitranslmed.abf3917. nihFormattedCitation: Dixit D, Prager BC, Gimple RC, Miller TE, Wu Q, Yomtoubian S, Kidwell RL, Lv D, Zhao L, Qiu Z, Zhang G, Lee D, Park DE, Wechsler-Reya RJ, Wang X, Bao S, Rich JN. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. Sci Transl Med. 2022;14(626):eabf3917.. PubMed PMID: 34985972.
. Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition. Sci Adv. 2021-11-12;7(46):eabi5790. doi: 10.1126/sciadv.abi5790. nihFormattedCitation: Cascio S, Chandler C, Zhang L, Sinno S, Gao B, Onkar S, Bruno TC, Vignali DAA, Mahdi H, Osmanbeyoglu HU, Vlad AM, Coffman LG, Buckanovich RJ. Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition. Sci Adv. 2021;7(46):eabi5790. PMCID: PMC8589308.. PubMed PMID: 34767446; PMCID: PMC8589308.
. Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. J Exp Med. 2021-11-01;218(11): doi: 10.1084/jem.20202669. nihFormattedCitation: Zhang G, Dong Z, Gimple RC, Wolin A, Wu Q, Qiu Z, Wood LM, Shen JZ, Jiang L, Zhao L, Lv D, Prager BC, Kim LJY, Wang X, Zhang L, Anderson RL, Moore JK, Bao S, Keller TH, Lin G, Kang C, Hamerlik P, Zhao R, Ford HL, Rich JN. Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. J Exp Med. 2021;218(11). PMCID: PMC8504185.. PubMed PMID: 34617969; PMCID: PMC8504185.
. SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators. Nucleic Acids Res. 2021-09-27;49(17):9633-9647. doi: 10.1093/nar/gkab745. nihFormattedCitation: Ma X, Somasundaram A, Qi Z, Hartman DJ, Singh H, Osmanbeyoglu HU. SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators. Nucleic Acids Res. 2021;49(17):9633-9647. PMCID: PMC8464045.. PubMed PMID: 34500467; PMCID: PMC8464045.
. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology. 2021-08-01;74(2):741-759. doi: 10.1002/hep.31730. nihFormattedCitation: Tao J, Krutsenko Y, Moghe A, Singh S, Poddar M, Bell A, Oertel M, Singhi AD, Geller D, Chen X, Lujambio A, Liu S, Monga SP. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology. 2021;74(2):741-759. PMCID: PMC8326305.. PubMed PMID: 33529367; PMCID: PMC8326305.
. A delicate initiation: Lipolysis of lipid droplets fuels glioblastoma. Mol Cell. 2021-07-01;81(13):2686-2687. doi: 10.1016/j.molcel.2021.06.013. nihFormattedCitation: Yang K, Rich JN. A delicate initiation: Lipolysis of lipid droplets fuels glioblastoma. Mol Cell. 2021;81(13):2686-2687.. PubMed PMID: 34214442.
. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-002417. nihFormattedCitation: Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021;9(7). PMCID: PMC8287618.. PubMed PMID: 34272305; PMCID: PMC8287618.
. 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening. Mol Cancer Ther. 2021-06-01;20(6):1210-1219. doi: 10.1158/1535-7163.MCT-20-0880. nihFormattedCitation: Wan L, Yin J, Skoko J, Schwartz R, Zhang M, LeDuc PR, Neumann CA. 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening. Mol Cancer Ther. 2021;20(6):1210-1219. PMCID: PMC8172531.. PubMed PMID: 33785649; PMCID: PMC8172531.
. A vaccine for glioma. Nat Cancer. 2021-06-01;2(6):584-586. doi: 10.1038/s43018-021-00228-2. nihFormattedCitation: Agnihotri S, Yang K, Mitchell DA, Rich JN. A vaccine for glioma. Nat Cancer. 2021;2(6):584-586.. PubMed PMID: 35121939.
. Integrative microphysiological tissue systems of cancer metastasis to the liver. Semin Cancer Biol. 2021-06-01;71157-169. doi: 10.1016/j.semcancer.2020.06.010. nihFormattedCitation: Clark AM, Allbritton NL, Wells A. Integrative microphysiological tissue systems of cancer metastasis to the liver. Semin Cancer Biol. 2021;71:157-169. PMCID: PMC7750290.. PubMed PMID: 32580025; PMCID: PMC7750290.
. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. Cancer Discov. 2021-05-01;11(5):1192-1211. doi: 10.1158/2159-8290.CD-20-1243. nihFormattedCitation: Wang D, Prager BC, Gimple RC, Aguilar B, Alizadeh D, Tang H, Lv D, Starr R, Brito A, Wu Q, Kim LJY, Qiu Z, Lin P, Lorenzini MH, Badie B, Forman SJ, Xie Q, Brown CE, Rich JN. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. Cancer Discov. 2021;11(5):1192-1211. PMCID: PMC8406797.. PubMed PMID: 33328215; PMCID: PMC8406797.
. Transcription factor chromatin profiling genome-wide using uliCUT&RUN in single cells and individual blastocysts. Nat Protoc. 2021-05-01;16(5):2633-2666. doi: 10.1038/s41596-021-00516-2. nihFormattedCitation: Patty BJ, Hainer SJ. Transcription factor chromatin profiling genome-wide using uliCUT&RUN in single cells and individual blastocysts. Nat Protoc. 2021;16(5):2633-2666. PMCID: PMC8177051.. PubMed PMID: 33911257; PMCID: PMC8177051.
. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021-04-01;4(4):e216322. doi: 10.1001/jamanetworkopen.2021.6322. nihFormattedCitation: Carleton N, Zou J, Fang Y, Koscumb SE, Shah OS, Chen F, Beriwal S, Diego EJ, Brufsky AM, Oesterreich S, Shapiro SD, Ferris R, Emens LA, Tseng G, Marroquin OC, Lee AV, McAuliffe PF. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2021;4(4):e216322. PMCID: PMC8050744.. PubMed PMID: 33856473; PMCID: PMC8050744.
. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. J Clin Invest. 2021-02-15;131(4): doi: 10.1172/JCI141335. nihFormattedCitation: Lv S, Song Q, Chen G, Cheng E, Chen W, Cole R, Wu Z, Pascal LE, Wang K, Wipf P, Nelson JB, Wei Q, Huang W, Wang Z. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. J Clin Invest. 2021;131(4). PMCID: PMC7880411.. PubMed PMID: 33332287; PMCID: PMC7880411.
. LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Sci Adv. 2021-02-01;7(7): doi: 10.1126/sciadv.abb3555. nihFormattedCitation: Guo W, Wang Y, Yang M, Wang Z, Wang Y, Chaurasia S, Wu Z, Zhang M, Yadav GS, Rathod S, Concha-Benavente F, Fernandez C, Li S, Xie W, Ferris RL, Kammula US, Lu B, Yang D. LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Sci Adv. 2021;7(7). PMCID: PMC7875530.. PubMed PMID: 33568470; PMCID: PMC7875530.
. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2021-02-01;11(2):480-499. doi: 10.1158/2159-8290.CD-20-0331. nihFormattedCitation: Dixit D, Prager BC, Gimple RC, Poh HX, Wang Y, Wu Q, Qiu Z, Kidwell RL, Kim LJY, Xie Q, Vitting-Seerup K, Bhargava S, Dong Z, Jiang L, Zhu Z, Hamerlik P, Jaffrey SR, Zhao JC, Wang X, Rich JN. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2021;11(2):480-499. PMCID: PMC8110214.. PubMed PMID: 33023892; PMCID: PMC8110214.
. Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors. Theranostics. 2021-01-20;11(8):3540-3551. doi: 10.7150/thno.51885. nihFormattedCitation: Grimley E, Cole AJ, Luong TT, McGonigal SC, Sinno S, Yang D, Bernstein KA, Buckanovich RJ. Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors. Theranostics. 2021;11(8):3540-3551. PMCID: PMC7914353.. PubMed PMID: 33664846; PMCID: PMC7914353.
. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. Cancer Res. 2021-01-15;81(2):268-281. doi: 10.1158/0008-5472.CAN-20-0696. nihFormattedCitation: Chen F, Ding K, Priedigkeit N, Elangovan A, Levine KM, Carleton N, Savariau L, Atkinson JM, Oesterreich S, Lee AV. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. Cancer Res. 2021;81(2):268-281. PMCID: PMC7856056.. PubMed PMID: 33148662; PMCID: PMC7856056.
. Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. J Clin Oncol. 2020-12-10;38(35):4208-4218. doi: 10.1200/JCO.20.00744. nihFormattedCitation: Burns TF, Borghaei H, Ramalingam SS, Mok TS, Peters S. Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. J Clin Oncol. 2020;38(35):4208-4218. PMCID: PMC7723684.. PubMed PMID: 33104438; PMCID: PMC7723684.
. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020-10-27;12(1):90. doi: 10.1186/s13073-020-00787-6. nihFormattedCitation: Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020;12(1):90. PMCID: PMC7590690.. PubMed PMID: 33106165; PMCID: PMC7590690.
. Three dimensional engineered models to study hypoxia biology in breast cancer. Cancer Lett. 2020-10-10;490124-142. doi: 10.1016/j.canlet.2020.05.030. nihFormattedCitation: Aggarwal V, Miranda O, Johnston PA, Sant S. Three dimensional engineered models to study hypoxia biology in breast cancer. Cancer Lett. 2020;490:124-142. PMCID: PMC7442747.. PubMed PMID: 32569616; PMCID: PMC7442747.
. Live-cell imaging and analysis reveal cell phenotypic transition dynamics inherently missing in snapshot data. Sci Adv. 2020-09-01;6(36): doi: 10.1126/sciadv.aba9319. nihFormattedCitation: Wang W, Douglas D, Zhang J, Kumari S, Enuameh MS, Dai Y, Wallace CT, Watkins SC, Shu W, Xing J. Live-cell imaging and analysis reveal cell phenotypic transition dynamics inherently missing in snapshot data. Sci Adv. 2020;6(36). PMCID: PMC7473671.. PubMed PMID: 32917609; PMCID: PMC7473671.
. Spatial domain analysis predicts risk of colorectal cancer recurrence and infers associated tumor microenvironment networks. Nat Commun. 2020-07-14;11(1):3515. doi: 10.1038/s41467-020-17083-x. nihFormattedCitation: Uttam S, Stern AM, Sevinsky CJ, Furman S, Pullara F, Spagnolo D, Nguyen L, Gough A, Ginty F, Lansing Taylor D, Chakra Chennubhotla S. Spatial domain analysis predicts risk of colorectal cancer recurrence and infers associated tumor microenvironment networks. Nat Commun. 2020;11(1):3515. PMCID: PMC7360741.. PubMed PMID: 32665557; PMCID: PMC7360741.
. A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. Nat Commun. 2020-07-03;11(1):3340. doi: 10.1038/s41467-020-17159-8. nihFormattedCitation: Zhao Y, Wu D, Jiang D, Zhang X, Wu T, Cui J, Qian M, Zhao J, Oesterreich S, Sun W, Finkel T, Li G. A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. Nat Commun. 2020;11(1):3340. PMCID: PMC7334201.. PubMed PMID: 32620845; PMCID: PMC7334201.
. The cryo-EM structure of the SNX-BAR Mvp1 tetramer. Nat Commun. 2020-03-20;11(1):1506. doi: 10.1038/s41467-020-15110-5. nihFormattedCitation: Sun D, Varlakhanova NV, Tornabene BA, Ramachandran R, Zhang P, Ford MGJ. The cryo-EM structure of the SNX-BAR Mvp1 tetramer. Nat Commun. 2020;11(1):1506. PMCID: PMC7083883.. PubMed PMID: 32198400; PMCID: PMC7083883.
. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics. 2020-03-04;10(9):3939-3951. doi: 10.7150/thno.39341. nihFormattedCitation: Wu Z, Li S, Tang X, Wang Y, Guo W, Cao G, Chen K, Zhang M, Guan M, Yang D. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics. 2020;10(9):3939-3951. PMCID: PMC7086350.. PubMed PMID: 32226530; PMCID: PMC7086350.
. Differences in the intrinsic spatial dynamics of the chromatin contribute to cell differentiation. Nucleic Acids Res. 2020-02-20;48(3):1131-1145. doi: 10.1093/nar/gkz1102. nihFormattedCitation: Zhang S, Chen F, Bahar I. Differences in the intrinsic spatial dynamics of the chromatin contribute to cell differentiation. Nucleic Acids Res. 2020;48(3):1131-1145. PMCID: PMC7026660.. PubMed PMID: 31828312; PMCID: PMC7026660.
. An evolving paradigm of cancer stem cell hierarchies: therapeutic implications. Theranostics. 2020-02-10;10(7):3083-3098. doi: 10.7150/thno.41647. nihFormattedCitation: Cole AJ, Fayomi AP, Anyaeche VI, Bai S, Buckanovich RJ. An evolving paradigm of cancer stem cell hierarchies: therapeutic implications. Theranostics. 2020;10(7):3083-3098. PMCID: PMC7053211.. PubMed PMID: 32194856; PMCID: PMC7053211.
. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein. J Clin Invest. 2020-02-03;130(2):1036-1051. doi: 10.1172/JCI97040. nihFormattedCitation: Cheng J, Klei LR, Hubel NE, Zhang M, Schairer R, Maurer LM, Klei HB, Kang H, Concel VJ, Delekta PC, Dang EV, Mintz MA, Baens M, Cyster JG, Parameswaran N, Thome M, Lucas PC, McAllister-Lucas LM. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein. J Clin Invest. 2020;130(2):1036-1051. PMCID: PMC6994119.. PubMed PMID: 31961340; PMCID: PMC6994119.
. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. J Immunother Cancer. 2019-10-18;7(1):265. doi: 10.1186/s40425-019-0755-1. nihFormattedCitation: Zhu L, Narloch JL, Onkar S, Joy M, Broadwater G, Luedke C, Hall A, Kim R, Pogue-Geile K, Sammons S, Nayyar N, Chukwueke U, Brastianos PK, Anders CK, Soloff AC, Vignali DAA, Tseng GC, Emens LA, Lucas PC, Blackwell KL, Oesterreich S, Lee AV. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. J Immunother Cancer. 2019;7(1):265. PMCID: PMC6798422.. PubMed PMID: 31627744; PMCID: PMC6798422.
. No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer. J Clin Oncol. 2019-10-10;37(29):2707-2708. doi: 10.1200/JCO.19.01650. nihFormattedCitation: Buckanovich RJ, Rustin G, Uppal S, Olawaiye AB, Kelley JL, Berger JL, Landen CN. No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer. J Clin Oncol. 2019;37(29):2707-2708.. PubMed PMID: 31449471.
. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nat Commun. 2019-09-25;10(1):4369. doi: 10.1038/s41467-019-12291-6. nihFormattedCitation: Osmanbeyoglu HU, Shimizu F, Rynne-Vidal A, Alonso-Curbelo D, Chen HA, Wen HY, Yeung TL, Jelinic P, Razavi P, Lowe SW, Mok SC, Chiosis G, Levine DA, Leslie CS. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nat Commun. 2019;10(1):4369. PMCID: PMC6761109.. PubMed PMID: 31554806; PMCID: PMC6761109.
. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019-07-11;10(1):3055. doi: 10.1038/s41467-019-11044-9. nihFormattedCitation: Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019;10(1):3055. PMCID: PMC6624260.. PubMed PMID: 31296870; PMCID: PMC6624260.
. Monoamine transporters: structure, intrinsic dynamics and allosteric regulation. Nat Struct Mol Biol. 2019-07-01;26(7):545-556. doi: 10.1038/s41594-019-0253-7. nihFormattedCitation: Cheng MH, Bahar I. Monoamine transporters: structure, intrinsic dynamics and allosteric regulation. Nat Struct Mol Biol. 2019;26(7):545-556. PMCID: PMC6712983.. PubMed PMID: 31270469; PMCID: PMC6712983.
. Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor Migration. Cancer Res. 2019-06-01;79(11):2962-2977. doi: 10.1158/0008-5472.CAN-18-3151. nihFormattedCitation: Singh M, Tian XJ, Donnenberg VS, Watson AM, Zhang J, Stabile LP, Watkins SC, Xing J, Sant S. Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor Migration. Cancer Res. 2019;79(11):2962-2977. PMCID: PMC6548579.. PubMed PMID: 30952634; PMCID: PMC6548579.
. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations. Cell Metab. 2019-05-07;29(5):1135-1150.e6. doi: 10.1016/j.cmet.2019.01.002. nihFormattedCitation: Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Görg B, Häussinger D, Chen X, Monga SP. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations. Cell Metab. 2019;29(5):1135-1150.e6. PMCID: PMC6506359.. PubMed PMID: 30713111; PMCID: PMC6506359.
. Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. Redox Biol. 2019-04-01;22101132. doi: 10.1016/j.redox.2019.101132. nihFormattedCitation: Khoo NKH, Fazzari M, Chartoumpekis DV, Li L, Guimaraes DA, Arteel GE, Shiva S, Freeman BA. Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. Redox Biol. 2019;22:101132. PMCID: PMC6375063.. PubMed PMID: 30769284; PMCID: PMC6375063.
. Hepatic Zonation Now on Hormones! Hepatology. 2019-03-01;69(3):1339-1342. doi: 10.1002/hep.30221. nihFormattedCitation: Ko S, Monga SP. Hepatic Zonation Now on Hormones! Hepatology. 2019;69(3):1339-1342. PMCID: PMC6379153.. PubMed PMID: 30120897; PMCID: PMC6379153.
. Hepatocyte-Specific β-Catenin Deletion During Severe Liver Injury Provokes Cholangiocytes to Differentiate Into Hepatocytes. Hepatology. 2019-02-01;69(2):742-759. doi: 10.1002/hep.30270. nihFormattedCitation: Russell JO, Lu WY, Okabe H, Abrams M, Oertel M, Poddar M, Singh S, Forbes SJ, Monga SP. Hepatocyte-Specific β-Catenin Deletion During Severe Liver Injury Provokes Cholangiocytes to Differentiate Into Hepatocytes. Hepatology. 2019;69(2):742-759. PMCID: PMC6351199.. PubMed PMID: 30215850; PMCID: PMC6351199.
. Mitochondrial quality control mediated by PINK1 and PRKN: links to iron metabolism and tumor immunity. Autophagy. 2019-01-01;15(1):172-173. doi: 10.1080/15548627.2018.1526611. nihFormattedCitation: Kang R, Xie Y, Zeh HJ, Klionsky DJ, Tang D. Mitochondrial quality control mediated by PINK1 and PRKN: links to iron metabolism and tumor immunity. Autophagy. 2019;15(1):172-173. PMCID: PMC6287677.. PubMed PMID: 30252570; PMCID: PMC6287677.
. An Insulin-Responsive Sensor in the SIRT1 Disordered Region Binds DBC1 and PACS-2 to Control Enzyme Activity. Mol Cell. 2018-12-20;72(6):985-998.e7. doi: 10.1016/j.molcel.2018.10.007. nihFormattedCitation: Krzysiak TC, Thomas L, Choi YJ, Auclair S, Qian Y, Luan S, Krasnow SM, Thomas LL, Koharudin LMI, Benos PV, Marks DL, Gronenborn AM, Thomas G. An Insulin-Responsive Sensor in the SIRT1 Disordered Region Binds DBC1 and PACS-2 to Control Enzyme Activity. Mol Cell. 2018;72(6):985-998.e7. PMCID: PMC6309500.. PubMed PMID: 30415949; PMCID: PMC6309500.
. Response to comment on "ALK is a therapeutic target for lethal sepsis". Sci Transl Med. 2018-12-12;10(471): doi: 10.1126/scitranslmed.aas9817. nihFormattedCitation: Tang D, Kang R. Response to comment on "ALK is a therapeutic target for lethal sepsis". Sci Transl Med. 2018;10(471).. PubMed PMID: 30541792.
. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res. 2018-11-01;78(21):6209-6222. doi: 10.1158/0008-5472.CAN-18-1416. nihFormattedCitation: Tasdemir N, Bossart EA, Li Z, Zhu L, Sikora MJ, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res. 2018;78(21):6209-6222. PMCID: PMC6507416.. PubMed PMID: 30228172; PMCID: PMC6507416.
. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res. 2018-10-15;24(20):5165-5177. doi: 10.1158/1078-0432.CCR-18-0279. nihFormattedCitation: Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, Katz TA, Boone DN, Jacobsen BM, Atkinson JM, Oesterreich S, Lee AV. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res. 2018;24(20):5165-5177. PMCID: PMC6821389.. PubMed PMID: 29941485; PMCID: PMC6821389.
. BECN1 is a new driver of ferroptosis. Autophagy. 2018-09-06;14(12):2173-2175. doi: 10.1080/15548627.2018.1513758. nihFormattedCitation: Kang R, Zhu S, Zeh HJ, Klionsky DJ, Tang D. BECN1 is a new driver of ferroptosis. Autophagy. 2018;14(12):2173-2175. PMCID: PMC6984768.. PubMed PMID: 30145930; PMCID: PMC6984768.
. Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun. 2018-08-09;9(1):3192. doi: 10.1038/s41467-018-05495-9. nihFormattedCitation: Wang Y, Wang Z, Xu J, Li J, Li S, Zhang M, Yang D. Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun. 2018;9(1):3192. PMCID: PMC6085336.. PubMed PMID: 30093685; PMCID: PMC6085336.
. Novel Genetic Activation Screening in Liver Repopulation and Cancer: Now CRISPR Than Ever! Hepatology. 2018-08-01;68(2):408-411. doi: 10.1002/hep.30084. nihFormattedCitation: Preziosi M, Monga SP. Novel Genetic Activation Screening in Liver Repopulation and Cancer: Now CRISPR Than Ever! Hepatology. 2018;68(2):408-411. PMCID: PMC6097894.. PubMed PMID: 29742805; PMCID: PMC6097894.
